Gsa Capital Partners LLP Contrafect Corp Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$3.19 - $4.43 $347,869 - $483,091	-109,050 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$3.58 - $4.9 $131,923 - $180,565	36,850 Added 51.04%	109,050 $480,000
Q1 2021 May 10, 2021	SELL	$4.46 - $6.68 $169,038 - $253,178	-37,901 Reduced 34.42%	72,200 $347,000
Q4 2020 Feb 03, 2021	BUY	$5.05 - $6.4 $199,111 - $252,339	39,428 Added 55.79%	110,101 $556,000
Q3 2020 Nov 06, 2020	BUY	$5.05 - $6.99 $295,041 - $408,383	58,424 Added 476.97%	70,673 $373,000
Q2 2020 Aug 11, 2020	BUY	$4.69 - $7.81 $57,447 - $95,664	12,249 New	12,249 $78,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.